Accuray Hits Milestone with 100 Patients Treated Using Tomo C System in China

Accuray Achieves Milestone in Cancer Treatment in China

Accuray Incorporated, a leading innovator in oncology treatment solutions, proudly announces a significant achievement: Shandong Cancer Hospital and Institute has successfully treated its first 100 patients using the Tomo® C Radiation Treatment Delivery System. This cutting-edge system, developed through a joint venture between Accuray and CNNC, marks a pivotal moment for cancer care in China, a market that is rapidly expanding due to increased cancer diagnoses.

According to projections, the number of new cancer cases in China is expected to rise by nearly 47% over the next two decades, culminating in an alarming estimate of 7.1 million diagnoses by 2045, compared to approximately 4.8 million in 2022. These numbers highlight the urgent need for sophisticated radiotherapy technology such as the Tomo C System, which has already shown its potential in handling a wide array of cancer cases.

Suzanne Winter, President and CEO of Accuray, expressed her pride in the collaboration with Shandong Cancer Hospital, stating, "We are delighted to support their team in enhancing cancer treatment capabilities with the new Tomo C System. The range of cancers treated among these first 100 patients signifies a critical step forward, and the system's rapid treatment speed will potentially allow healthcare providers to treat more patients daily."

The Tomo C System has been designed with advanced technology that promises personalized, fast, and effective cancer care. Each component integrates seamlessly, enabling medical teams to deliver ultra-precise treatments while maximizing patient throughput. This is critical in a context where timely treatment is key to better outcomes in cancer care.

Prof. Yu, President of Shandong Cancer Hospital, emphasized the significance of this new technology, stating, "The introduction of the Tomo C Radiation Treatment Delivery System is transformational for precision radiotherapy, positioning us to treat an average of 95 patient fractions per day. These advancements help us fulfil our commitment to the ‘Healthy China Initiative’ and elevate our cancer care standards."

Shandong Cancer Hospital and Institute is renowned within China, having served over 400,000 patients annually since its founding in 1958. The hospital prides itself on its collaborations with global leaders, including the esteemed MD Anderson Cancer Center in the US, reinforcing its commitment to innovative cancer treatments and research.

Continuously innovating, Accuray focuses on expanding the capabilities of radiation therapy to improve patient outcomes. The company has emphasized its ongoing commitment to provide healthcare professionals with the essential tools necessary for offering exceptional care. By embracing advanced treatment technologies like the Tomo C System, Accuray not only enhances the clinical capacity of institutions like Shandong Cancer Hospital but also contributes significantly to addressing the pressing healthcare needs in China.

With the Tomo C System being the first of its kind in this region, Accuray is poised to take a significant role in shaping the future of cancer treatment in China. By bridging the gap between advanced technology and patient care, companies like Accuray continue to demonstrate their dedication to improving lives through medical innovation.

For more information on Accuray and its innovative treatment solutions, visit www.accuray.com.

This announcement marks a crucial step towards combating the rising cancer epidemic in China, showcasing the potential of modern medical technology in transforming patient care.